Related Experiment Videos

Should circulating anticoagulant [AKA anti-phospholipid] assays be a routine component of well-patient assessment?

G Kubitz1, B M Rothschild

  • 1Foot and Ankle Clinic, Youngstown Osteopathic Hospital, Ohio, USA.

Comprehensive Therapy
|December 24, 1997
PubMed

Insights

Circulating anticoagulants, including anticardiolipin antibodies and lupus anticoagulants, are linked to serious health issues like blood clots and pregnancy complications. This study surveyed 200 patients to investigate these risks.

Area of Science:

  • Cardiology
  • Hematology
  • Obstetrics

Background:

  • Circulating anticoagulants are established risk factors for thrombosis and adverse pregnancy outcomes.
  • Understanding the prevalence of specific anticoagulants is crucial for risk assessment.

Purpose of the Study:

  • To retrospectively survey the prevalence of anticardiolipin antibody and lupus anticoagulant in a patient cohort.
  • To assess the association of these anticoagulants with thrombotic events and pregnancy complications.

Main Methods:

  • Retrospective survey of 200 consecutive patients.
  • Analysis of anticardiolipin antibody and lupus anticoagulant presence.
  • Correlation with thrombotic events and pregnancy complications.

Main Results:

  • The study identified the prevalence of anticardiolipin antibody and lupus anticoagulant in the surveyed population.
  • Results indicate a significant association between these anticoagulants and increased risk of thrombotic problems and pregnancy complications.

Conclusions:

  • Circulating anticoagulants, specifically anticardiolipin antibody and lupus anticoagulant, represent a significant risk factor for patients.
  • Clinical vigilance for these anticoagulants is warranted in patients with a history of thrombotic events or pregnancy complications.

Related Concept Videos